Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • After Kotak and UTI, SBI Mutual Fund halts silver ETF FoF subscriptions
    • Winning move for investment into equity MF: Go for funds with lower probability of loss if you are a conservative investor
    • Gold and Silver ETFs drive passive flows in September 2025
    • The politics premium is punishing bonds from Paris to Tokyo
    • Malaysia concludes Expo 2025 Osaka with RM24.45b in potential trade and investments, says Miti sec-gen
    • Bitcoin’s Flash Crash Over Weekend Prompts Analyst To Sound Warning on BTC ETFs: Continuous Liquidity Essential To ‘Prudent Risk Management’ – iShares Bitcoin Trust (NASDAQ:IBIT)
    • Buying gold every year on Diwali is like an SIP: Don’t overinvest and stick to asset allocation
    • Crypto’s Weekend Wipeout Exposes a Glaring Flaw in Wall Street’s Bitcoin ETFs
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Bonds»Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal
    Bonds

    Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

    August 12, 2024


    Key Takeaways

    • Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly worth $5 billion.
    • The company’s stock was upgraded by Deutsche Bank analysts following its quarterly results last week.
    • Lilly shares jumped early in the day but closed in the red.

    Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.

    Deutsche Bank analysts called the drugmaker a “high growth unicorn” and upgraded its shares to a buy rating. The bump was based in part on sales of the weight-loss drug Mounjaro, which more than tripled to $3.09 billion when the company reported earnings last week

    The firm upgraded its price target to $1,025 from $725, a nearly 15% premium to Lilly’s Friday closing price. Shares rose above $904 Monday morning. 

    Bonds Help Fund Morphic Acquisition

    The stock gave back its early gains after Bloomberg in a report said the company would sell $5 billion in bonds to help pay for its $3.2 billion acquisition of Morphic (MORF). Lilly in a regulatory filing confirmed the sale but offered fewer details.

    The deal, announced last month, adds Morphic’s flagship developmental drug for inflammatory bowel disease to Lilly’s portfolio. The company is also developing molecules intended to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.

    Lilly will sell bonds in five chunks, including a 40-year note with a 1% higher yield than a U.S. Treasury note, according to the report. Corporate bonds are typically seen as riskier than U.S. government bonds, so they usually have higher interest rates to compensate.

    An Eli Lilly spokesperson declined to comment. Shares of the company closed Monday’s session down less than 1%,



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    The politics premium is punishing bonds from Paris to Tokyo

    October 12, 2025

    Indonesian Government Issues USD1.85 Billion and EUR600 Million in Global Bonds

    October 11, 2025

    Sovereign Bonds: Planting for Growth, Reaping Stability

    October 11, 2025
    Leave A Reply Cancel Reply

    Top Posts

    The Shifting Landscape of Art Investment and the Rise of Accessibility: The London Art Exchange

    September 11, 2023

    Charlie Cobham: The Art Broker Extraordinaire Maximizing Returns for High Net Worth Clients

    February 12, 2024

    The politics premium is punishing bonds from Paris to Tokyo

    October 12, 2025

    The Unyielding Resilience of the Art Market: A Historical and Contemporary Perspective

    November 19, 2023
    Don't Miss
    Mutual Funds

    After Kotak and UTI, SBI Mutual Fund halts silver ETF FoF subscriptions

    October 13, 2025

    Following Kotak Mutual Fund and UTI Mutual Fund, SBI Mutual Fund has now suspended fresh…

    Winning move for investment into equity MF: Go for funds with lower probability of loss if you are a conservative investor

    October 13, 2025

    Gold and Silver ETFs drive passive flows in September 2025

    October 12, 2025

    The politics premium is punishing bonds from Paris to Tokyo

    October 12, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    South Korean regulator to review crypto ETF approval: report

    October 10, 2024

    Europe: cross-border property investment by region 2023

    July 26, 2024

    Should you opt for mutual funds to accumulate sufficient wealth for retirement? Experts weigh in

    September 7, 2025
    Our Picks

    After Kotak and UTI, SBI Mutual Fund halts silver ETF FoF subscriptions

    October 13, 2025

    Winning move for investment into equity MF: Go for funds with lower probability of loss if you are a conservative investor

    October 13, 2025

    Gold and Silver ETFs drive passive flows in September 2025

    October 12, 2025
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    ₹10,000 monthly SIP in this mutual fund has grown to ₹1.52 crore in 22 years

    September 17, 2025
    © 2025 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.